Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.11 (
CD10
)
9,792
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An immortalized hypothalamic neuronal cell line was recently developed by genetically targeting the expression of the simian virus-40 large T-antigen in
LHRH
neurons. These GT1 cells were subcloned to GT1-1, GT1-3, and GT1-7 cells, and they have been shown to express the mRNA for pro-
LHRH
and secrete
LHRH
-like immunoreactive (IR) materials into the media. The purpose of our study was to biochemically and immunologically characterize the IR materials within and secreted from these cells. Both
LHRH
- and GnRH-associated peptide (GAP)-like IR materials were present and were secreted from these four cell lines. Up to 3% of the total cellular protein was composed of
LHRH
and GAP materials. When materials from the cell lysate and media were separated according to mol wt (Mr), at least three different pro-
LHRH
species were detected. These precursors contained both
LHRH
- and GAP-like IR determinants, and they eluted in the void volume and at approximately 10,000-12,000 and 8,400-8,500 Mr. A material that contained GAP-like IR eluted at approximately 6,500-6,800 Mr. This species is probably mouse GAP-(1-56) because it eluted on a reverse phase column in the approximate position of rat GAP-(1-56). Cell lysates contained a single
LHRH
-like IR form which coeluted on a size-exclusion column with synthetic
LHRH
. This material stimulated secretion of LH from anterior pituitary cells in a dose-response manner. By comparison, two different molecular forms of
LHRH
were detected in media at approximately 1,500 and 540 Mr. HPLC analyses revealed these peaks to be heterogeneous and to contain at least (Gln1)
LHRH
-(Gly11,Lys12,Arg13), (Gln1)
LHRH
-(Gly1,Lys12),
LHRH
-(Gly11), and
LHRH
. These experiments demonstrate that the cells contain and secrete multiple molecular forms of the pro-
LHRH
and that processing of the prohormone must involve 1) cleavage by an
endopeptidase
to give GAP-(1-56) and a C-terminally extended
LHRH
, 2) removal of C-terminal basic amino acids by a carboxypeptidase, 3) amidation of
LHRH
-(Gly11) to
LHRH
, and 4) cyclization of glutamine to pyroglutamate at the N-terminal of
LHRH
. These results provide the first evidence for intermediates in the metabolic pathway of pro-
LHRH
to
LHRH
.
...
PMID:Metabolism of pro-luteinizing hormone-releasing hormone in immortalized hypothalamic neurons. 171 37
The susceptibility to hydrolysis of
LHRH
and the decapeptide analogue Antide has been compared. The hydrolysis of
LHRH
by pig kidney brush border membranes is inhibited by phosphoramidon (I50 = 5.6 nM) implicating
endopeptidase
-24.11 in the initiation of hydrolysis. Under conditions in which
LHRH
is fully degraded by brush border membranes, Antide was completely resistant to hydrolysis. Similar results were obtained with purified preparations of both
endopeptidase
-24.11 and angiotensin converting enzyme. These data confirm that the remarkable duration of action of Antide is due principally to its stability to hydrolysis by cell-surface peptidases.
...
PMID:Metabolic stability of the LHRH antagonist antide to cell-surface peptidases. 201 20
A novel fluorogenic substrate for the neutral metalloendopeptidase-24.15 (E.C.3.4.24.15; EP-24.15) was synthesized which allowed continuous assay of the enzyme. The substrate, Glutaryl-Phe-Ala-Ala-Phe-4-methoxynaphthylamide (G-FAAF-4MN) is cleaved at the Phe-Ala bond by EP-24.15 (Km = 0.026 mM). The product, AAF-4MN is subsequently hydrolyzed to its constituent amino acids and the potent fluorophore 4MN by aminopeptidase M. This method has allowed the measurement of the specific activity EP-24.15 within microdissected nuclei of rat brain. The enzyme was found to have a relatively broad distribution within brain nuclei, and the activity ranged from 15-80 nmol 4MN/mg prot/h in all areas examined. The activity of EP-24.15 was relatively high in the medial and lateral pre-optic nuclei, where potential substrates include the dynorphin-like peptides and
LHRH
. The activity of EP-24.15 was compared with that of
endopeptidase
-24.11 (E.C.3.4.24.11, 'enkephalinase', EP-24.11), another peptide-cleaving metalloenzyme. EP-24.11 appeared to have a much more narrow distribution, with very high specific activity in basal ganglia as well as in the supraoptic and suprachiasmatic nuclei.
...
PMID:Distribution of endopeptidase-24.15 in rat brain nuclei using a novel fluorogenic substrate: comparison with endopeptidase-24.11. 204 88
We and others have previously reported the existence of hypothalamic and anterior pituitary (AP) enzymes that degrade luteinizing hormone (LH)-releasing hormone (
LHRH
). We have further characterized these
LHRH
-degrading activities (LHRH-DA) and in addition assessed the role of
LHRH
-DA in
LHRH
release from median eminence (ME) tissue in vitro. Major
LHRH
-DA components were separated and their molecular weights were estimated by gel filtration chromatography. The role of
LHRH
-DA in
LHRH
release was determined by release studies from isolated ME, in the presence and absence of N-tosyl L-phenylalanine chloromethyl ketone (TPCK) and/or norepinephrine (NEpi). Degradation and in vitro release studies were performed by using
LHRH
analogs with amino acid substitutions at their 5-6 bond. Biological activity of these analogs was assessed by measuring in vitro LH release from dispersed anterior pituitary cells.
LHRH
-DA was determined by high-performance liquid chromatography; LH and
LHRH
were measured by radioimmunoassay. Separation of
LHRH
-DA by gel filtration chromatography yielded two major enzymatic activities: a Tyr5-Gly6 cleaving
endopeptidase
and a post-proline cleaving enzyme. Although
LHRH
-DA from AP and ME produced identical degradation fragments, the former had 3-fold greater specific activity than the latter.
LHRH
moieties with a Tyr5-Gly6 bond substitution were more resistant to enzymatic degradation and had greater biological activity than
LHRH
moieties with a Tyr5-Gly6 bond. TPCK decreased
LHRH
-DA and increased NEpi-stimulated in vitro release of
LHRH
from isolated ME.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Norepinephrine-stimulated in vitro release of luteinizing hormone-releasing hormone (LHRH) from median eminence tissue is facilitated by inhibition of LHRH-degrading activity in hens. 218 14
The pattern and kinetics of degradation of native salmon
gonadotropin-releasing hormone
(sGnRH) and mammalian leuteinizing hormone-releasing hormone (LHRH) by pituitary bound enzymes were studied in the gilthead seabream, Sparus aurata. sGnRH and LHRH were incubated for different periods of time with membrane or cytosolic fractions of pituitary homogenates. At the end of the incubation, the degradation mixture was fractionated on reverse-phase high-pressure liquid chromatography. The degradation products were identified by comparing their retention times to those of synthesized GnRH fragments and by analyzing their amino acid composition. The main GnRH degradative activity resides in the cytosolic fraction of the pituitary homogenate. Both sGnRH and LHRH are rapidly degraded by pituitary cytosol, with 78.3 and 87.7% of the peptides, respectively, cleaved after 3 hr of incubation. Maximal degradation of sGnRH occurred at a pH range of 7 to 8. The main initial products of degradation of sGnRH and LHRH are the 1-5, 6-10, and 1-9 fragments. This suggests the involvement of two site-specific peptidases, a Tyr5-Gly6
endopeptidase
and a Pro9-Gly10NH2 peptidase or postproline cleaving enzyme. While the 1-6 and 1-9 fragments undergo rapid secondary degradation, the 1-5 is relatively stable. Competition experiments suggest that the
endopeptidase
cleaving the sGnRH at the Tyr5-Gly6 bond is not specific to the neuropeptide and is probably a general proteolitic enzyme. However, the cleavage at the 9-10 bond has a high degree of specificity to the Pro9-Gly10NH2 sequence found in sGnRH. The two proposed pituitary peptidases of S. aurata have some characteristics similar to those of rat hypophyseal and hypothalamic GnRH cleaving enzymes. No differences are found in hypophyseal GnRH degradative activity between females with occytes undergoing previtellogenesis or advanced stages of vitellogenesis.
...
PMID:Degradation of gonadotropin-releasing hormones in the gilthead seabream, Sparus aurata. I. Cleavage of native salmon GnRH and mammalian LHRH in the pituitary. 220 10
The pattern and kinetics of degradation of native salmon
gonadotropin-releasing hormone
(sGnRH), mammalian luteinizing hormone-releasing hormone (LHRH), and some of their analogs by cytosolic enzymes of pituitary, kidney, and liver were studied in the gilthead seabream, Sparus aurata. The native peptides sGnRH and LHRH are rapidly degraded by all three tissues, LHRH being degraded faster than sGnRH. The kinetics of production of the peptide fragments suggest that initial cleavage of sGnRH and LHRH in the three studied tissues occurs at the 5-6 and 9-10 bonds. This indicates the initial activity of a Tyr5-Gly6
endopeptidase
and a Pro9-Gly10NH2 peptidase or postproline cleaving enzyme. Secondary degradation of the main initial fragments (1-5, 6-10, and 1-9) is more intensive in the kidney than in the pituitary or liver. Substitution of the position 6 amino acid glycine by a dextrorotatory (D) amino acid such as in the D-Trp6-LHRH renders the 5-6 bond resistant to cleavage. However, whereas [D-Trp6]-LHRH is intensively cleaved at the Pro9-Gly10NH2 bond by the pituitary, its cleavage at this site by the kidney and liver is slow. This suggests a low activity of the Pro9-Gly10NH2 peptidase in the kidney and liver as compared to the pituitary. When, in addition to the position 6 substitution, the carboxy terminus Pro9-Gly10NH2 is modified to Pro9NET, such as in the [D-Ala6-Pro9NET]-LHRH and the [D-Arg6-Pro9NET]-sGnRH, the 9-10 cleavage site is also blocked, resulting in GnRH analogs highly resistant to degradation. The relationships between susceptibility of the different forms of GnRH to enzymatic degradation by the pituitary, kidney, and liver and their relative biological activities in S. aurata are discussed. We conclude that increased resistance of GnRH analogs to enzymatic degradation contributes to their superactivity.
...
PMID:Degradation of gonadotropin-releasing hormones in the gilthead seabream, Sparus aurata. II. Cleavage of native salmon GnRH, mammalian LHRH, and their analogs in the pituitary, kidney, and liver. 220 11
From rat brain, a membrane bound substance P-degrading
endopeptidase
(SPE) was purified 1580 fold to near homogeneity. After extraction with 10 mM CHAPS, the enzyme preparation was subjected to ion exchange chromatography on DEAE-cellulose, adsorption chromatography on hydroxyapatite, gelfiltration through Ultrogel AcA 44 and FPLC on Mono Q. This enzyme of 70,000 molecular weight is optimally active at pH 7.5. Metal chelators (EDTA and EGTA) and sulfhydryl modifying reagents (N-ethylmaleimide and p-chloromercuriphenylsulfonic acid) are strongly inhibitory while the serine-protease inhibitor diisopropyl-fluorophosphate does not effect the enzyme activity. The enzyme is strongly inhibited by bacitracin but not by phosphoramidon and captopril. Degradation of substance P is strongly inhibited by neurotensin, somatostatin, ACTH 1-39, and less effectively by
LHRH
but not by Leucine-enkephalin. Substance P is preferentially hydrolyzed at the Gln6-Phe7 peptide bond but fragmentation at the Pro4-Gln5, Gln5-Gln6,Phe7-Phe8 and Gly9-Leu10 bonds was also observed.
...
PMID:A membrane bound substance P degrading endopeptidase from rat brain. 244 28
This study provides evidence that: 1)
LHRH
is degraded by renal brush border hydrolases, followed by reabsorption of oligopeptide metabolites in the proximal kidney tubule. 2) Peptide carriers are present in the luminal membrane of the proximal nephron, which apparently function to reabsorb oligopeptide metabolites resulting from hydrolysis of filtered peptides, including
LHRH
. 3) Renal brush border hydrolysis of
LHRH
involves cleavage at multiple sites by endopeptidases like angiotensin I-converting enzyme and
endopeptidase 24.11
; D-amino acid substituents at these sites may alter the expected cleavage pattern of the analogs. 4) A transcytotic pathway is present in the proximal nephron which is facilitated by endocytosis of cationic macromolecules; such a pathway may function to reabsorb hydrolytically resistant peptides, but the issue of potential toxicity must be clarified.
...
PMID:Renal handling of luteinizing hormone releasing hormone: a model for peptide transport and hydrolysis. 283 70
The concentration of
luteinizing hormone releasing hormone (LHRH)
(pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), which reaches the anterior pituitary via the hypothalamo-hypophyseal portal system, appears to be controlled in part by the rate of LHRH degradation within the hypothalamus and/or pituitary. Specific, active site-directed
endopeptidase
inhibitors synthesized in our laboratory were used to identify the enzyme(s) involved in LHRH degradation by hypothalamic and pituitary membrane preparations, and by an intact anterior pituitary tumor cell line (AtT20). Incubation of LHRH with pituitary and hypothalamic membrane preparations led to the formation of pGlu-His-Trp (
LHRH1
-3) as the main reaction product. Under the same conditions, addition to the incubation mixtures of captopril, an inhibitor of the angiotensin converting enzyme, led to accumulation of pGlu-His-Trp-Ser-Tyr (
LHRH1
-5) and, to a lesser extent, pGlu-His-Trp-Ser-Tyr (
LHRH1
-6). The degradation of LHRH and the formation of the N-terminal tri- and pentapeptides was blocked by N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate (cFP-AAF-pAB), a specific, active site directed inhibitor of
endopeptidase
-24.15. Some inhibition of LHRH degradation and formation of the N-terminal hexapeptide was also obtained in the presence of N-[1-carboxy-2-phenylethyl]-Phe-p-aminobenzoate (cFE-F-pAB), an inhibitor of
endopeptidase
-24.11. Similar results were obtained with AtT20 cell membranes and with intact AtT20 cells in monolayer culture. Following cleavage by endopeptidases the C-terminal part of LHRH was rapidly degraded by aminopeptidases. Superactive analogs of LHRH in which Gly6 was replaced by a D-amino acid are resistant to degradation by both
endopeptidase
-24.11 and -24.15. In vivo, when LHRH was injected directly into the third ventricle of rats, the presence of cFP-AAF-pAB inhibited LHRH degradation. It is concluded that LHRH degradation is primarily initiated by the membrane-bound form of
endopeptidase
-24.15 to yield pGlu-His-Trp-Ser-Tyr and to a lesser extent by
endopeptidase
-24.11 to yield pGlu-His-Trp-Ser-Tyr-Gly.
...
PMID:Endopeptidase-24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo. 329 5
Less than Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, the luteinizing hormone-releasing hormone,
LHRH
, is degraded in renal proximal tubules (PT) in vivo (rat) and in vitro (rabbit) to less than Glu-His (2), less than Glu-His-Trp (3), and less than Glu-His-Trp-Ser (4).
LHRH
may be cleaved by endopeptidases simultaneously at multiple bonds, or initially at Ser4-Tyr5 followed by carboxypeptidase hydrolysis of 4 to 3 and then 2. To distinguish between these mechanisms, [3H]
LHRH
analogues were incubated with rabbit renal brush-border membranes (BBM), microinfused into PT in vivo or in vitro, and products were analyzed by HPLC. [D-Ser4]
LHRH
was not cleaved at D Ser4-Tyr5 but yielded less than Glu-His-Trp-D-Ser-Tyr-Gly as the major metabolite plus 2 and 3. [D-Trp6]
LHRH
was cleaved by BBM and PT to 2 and 3, but not to 4. [D-Ser4, D-Trp6]
LHRH
was not cleaved by BBM, but was degraded to 2 by PT in vivo. Thus, D-amino acid substituents altered the expected cleavage pattern of these analogues. [3H]
LHRH
was cleaved by BBM or by
endopeptidase
-24.11 from porcine PT to metabolites 2, 4, small amounts of 3, and less than Glu-His-Trp-Ser-Tyr-Gly, but cleavage was strongly inhibited by the specific inhibitor phosphoramidon. Thus, normally
LHRH
may be cleaved in PT by
endopeptidase
-24.11 to 2 and 4, and by angiotensin I-converting enzyme to 3, its known cleavage site.
...
PMID:Effects of D-amino acid substituents on degradation of LHRH analogues by proximal tubule. 354 29
1
2
3
4
Next >>